
Turning Point Therapeutics TPTX
Quartalsbericht 2022-Q2
hinzugefügt 08.08.2022
Turning Point Therapeutics Gesamtes Eigenkapital 2011-2026 | TPTX
Gesamtes Eigenkapital Jährlich Turning Point Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 954 M | 1.11 B | 404 M | -48.4 M | -24.8 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.11 B | -48.4 M | 479 M |
Gesamtes Eigenkapital Vierteljährlich Turning Point Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 793 M | 891 M | 954 M | 1.02 B | 1.07 B | 1.1 B | 1.11 B | 1.11 B | 1.11 B | 1.11 B | 404 M | 404 M | 404 M | 404 M | -48.4 M | -48.4 M | -48.4 M | -48.4 M | -24.8 M | - | - | - | -8.66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.11 B | -48.4 M | 583 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | ||
|
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
Aptorum Group Limited
APM
|
21.1 M | $ 0.81 | 0.15 % | $ 4.42 M | ||
|
Aquestive Therapeutics
AQST
|
-60.2 M | $ 4.18 | 2.32 % | $ 363 M | ||
|
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | ||
|
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Ascendis Pharma A/S
ASND
|
884 M | $ 233.7 | -0.55 % | $ 5 B | ||
|
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.38 | 1.47 % | $ 8.13 B | ||
|
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | ||
|
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | ||
|
BioMarin Pharmaceutical
BMRN
|
5.66 B | $ 61.83 | -1.27 % | $ 11.7 B | ||
|
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | ||
|
Atea Pharmaceuticals
AVIR
|
439 M | $ 4.59 | -1.29 % | $ 387 M | ||
|
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | ||
|
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | ||
|
Capricor Therapeutics
CAPR
|
22.6 M | $ 28.51 | 2.15 % | $ 763 M | ||
|
CASI Pharmaceuticals
CASI
|
84.5 M | $ 0.32 | -60.0 % | $ 43.6 M | ||
|
Axsome Therapeutics
AXSM
|
88.3 M | $ 165.99 | -2.33 % | $ 8.26 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | ||
|
Catalyst Biosciences
CBIO
|
-15.8 M | $ 12.06 | -4.66 % | $ 794 M | ||
|
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | ||
|
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | ||
|
BioVie
BIVI
|
19 M | $ 1.25 | - | $ 1.85 M | ||
|
BeiGene, Ltd.
BGNE
|
3.33 B | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
18.3 B | $ 191.74 | -1.74 % | $ 28.1 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.02 M | - | -9.72 % | $ 5.89 M | ||
|
Baudax Bio
BXRX
|
-24.2 M | - | 0.59 % | $ 63 K | ||
|
Aptose Biosciences
APTO
|
-4.54 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | ||
|
Cellectis S.A.
CLLS
|
309 M | $ 4.23 | 6.28 % | $ 116 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-24.2 M | - | 17.91 % | $ 11.1 M |